Clinical trials: Microsatellite Stable
CRC (Colorectal Cancer)
A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy
The purpose of this study is to evaluate INCA33890 in the treatment of circulating tumor DNA-positive stage II/III microsatellite stable colorectal cancer after curative resection and chemotherapy.
- Trial name
- NEXERA-204 (NCT07823322)
- Testing
- INCA33890
- Volunteers
- 40 people
- Sponsor
- Incyte Corporation
Metastatic Colorectal Adenocarcinoma
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer
Managements for refractory proficient mismatch repair (pMMR) or microsatellite stable (MSS) metastatic colorectal cancer (mCRC) were still challenging and controversial.
- Trial name
- NCT05942768
- Testing
- regorafenib plus anti-PD-1 antibodies
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Hunan Cancer Hospital
Mismatch Repair-proficient, Colorectal Cancer Metastatic
Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer
Explore the efficacy of radiotherapy combined with Tislelizumab and irinotecan in MSS/pMMR inoperable recurrent and metastatic colorectal cancer patients; To evaluate the safety and tolerability of radiotherapy combined with…
- Conditions
- Mismatch Repair-proficient, Colorectal Cancer Metastatic, Microsatellite Stable
- Trial name
- NCT05160727
- Testing
- Tislelizumab, Irinotecan, radiotherapy
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Zhejiang Cancer Hospital
Endometrial Neoplasms, TP53 Gene Mutation
Translational Study of MSS, TP53 Mutation and Chromosome Instability Relationship in Endometrial Carcinoma
The objective is to understand the relationship between TP53 mutation, MSS and chromosome instability in endometrial cancer and the effect on clinical prognosis.We will collect a small amount of tumor tissue samples.
- Conditions
- Endometrial Neoplasms, TP53 Gene Mutation, Chromosomal Instability, Microsatellite Stable Endometrial Carcinoma
- Trial name
- NCT06521684
- Volunteers
- 110 people
- Sponsor
- Peking Union Medical College Hospital
Colorectal Cancer, Immunotherapy
mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC
Immunotherapy has achieved significant therapeutic effect in DNA mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC).
- Trial name
- BASKETⅡ (NCT04895137)
- Testing
- mFOLFOX6+Bevacizumab+PD-1 monoclonal antibody treatment combinations
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Neoplasms, Malignant
Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer
Cancer immunotherapy with immunostimulatory antibodies targeting the CTLA-4 or PD-1/PD-L1 pathways has demonstrated its efficacy in variable proportions of cancer.
- Trial name
- AVETUXIRI (NCT03608046)
- Testing
- Avelumab, Cetuximab Injection, Irinotecan
- Where
- 2 sites in Belgium
- Volunteers
- 59 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
This phase I/II trial studies the side effects and how well encorafenib, binimetinib, and nivolumab work in treating patients with microsatellite stable, BRAFV600E gene-mutated colorectal cancer that has spread to other places in…
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma
- Trial name
- NCT04044430
- Testing
- Binimetinib, Encorafenib, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- University of California, San Francisco
Rectal Adenocarcinoma
Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer
A Prospective Single-Arm Study of Short-Course Radiotherapy Followed by PD-1 Monoclonal Antibody, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil for Total Neoadjuvant Therapy in MSS Locally Advanced Low Rectal Cancer.
- Trial name
- SCRIPBOT (NCT06872606)
- Testing
- Pucotenlimab, Bevacizumab, Oxaliplatin
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sir Run Run Shaw Hospital
Colorectal Cancer Metastatic, Fecal Microbiota Transplantation
Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer
This research protocol outlines an exploratory study on the combination of early-life fecal microbiota transplantation (yFMT) with immunotherapy and chemotherapy in patients with microsatellite stable metastatic colorectal cancer…
- Trial name
- NCT07486492
- Testing
- yFMT
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
MSI Positive Colorectal Cancer, MSI Negative Colorectal Cancer
Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)
This study will be looking at whether MK-3475 (an antibody that blocks negative signals to T cells) is effective (anti-tumor activity) and safe in three different patient populations. These include: 1.
- Conditions
- MSI Positive Colorectal Cancer, MSI Negative Colorectal Cancer, MSI Positive Non-Colorectal Cancers
- Trial name
- NCT01876511
- Testing
- MK-3475
- Where
- 7 sites in United States
- Volunteers
- 113 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Anal Squamous Cell Carcinoma, Colorectal Neoplasms
Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
REFIT-MSS is a non-randomized, multicenter, open-label, multi-cohort, 2-stage, phase II trial to evaluate the efficacy and safety of regorafenib in combination with tislelizumab (referred as Rego-Tisle) in adult patients with…
- Conditions
- Anal Squamous Cell Carcinoma, Colorectal Neoplasms, Soft Tissue Sarcoma, Malignant Pleural Mesothelioma
- Trial name
- REFIT-MSS (NCT05582031)
- Testing
- Regorafenib in combination with Tislelizumab
- Sponsor
- Translational Research in Oncology
Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with metastatic or locally advanced microsatellite stable (MSS) colorectal cancer.
- Trial name
- NCT03642067
- Testing
- Nivolumab, Relatlimab
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Cancer, Endometrium Cancer
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
It's propose this pilot phase 2 study to explore the combination therapy of futibatinib with pembrolizumab in patients with metastatic microsatellite stable (MSS) endometrial carcinoma to provide a well-tolerated regimen for…
- Conditions
- Metastatic Cancer, Endometrium Cancer, Endometrial Carcinoma
- Trial name
- NCT05036681
- Testing
- Futibatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
The goal of this clinical trial is to explore the feasibility of a new mode of chemotherapy and bevacizumab induction therapy combined with immunotherapy as first-line treatment for patients with initially unresectable metastatic…
- Trial name
- FOBECAMS (NCT06176885)
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- yue junhan
Metastatic Colorectal Adenocarcinoma, Microsatellite Stable
Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer
This phase IIa trial studies how well rintatolimod and pembrolizumab works in treating patients with colorectal cancer that does not respond to treatment (refractory), has spread to other places in the body (metastatic), or…
- Conditions
- Metastatic Colorectal Adenocarcinoma, Microsatellite Stable, Mismatch Repair Proficient, Refractory Colorectal Adenocarcinoma
- Trial name
- NCT04119830
- Testing
- Pembrolizumab, Questionnaire Administration, Rintatolimod
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Advanced Colon Adenocarcinoma, Metastatic Colon Adenocarcinoma
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
This phase I trial studies the side effects and best dose of regorafenib when given together with ipilimumab and nivolumab in treating patients with microsatellite stable colorectal cancer that has spread to other places in the…
- Conditions
- Advanced Colon Adenocarcinoma, Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Colorectal Carcinoma
- Trial name
- NCT04362839
- Testing
- Ipilimumab, Nivolumab, Regorafenib
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- City of Hope Medical Center
Rectal Cancer
Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial
Microsatellite stable (MSS) locally advanced rectal cancer (LARC) remains a major therapeutic challenge despite advances in multimodal treatment.
- Trial name
- NCT07594925
- Testing
- Sintilimab, Chemotherapy Drugs, radiotherapy
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Locally Advanced Rectal Cancer
The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal Cancer
The study evaluates the addition of immunotherapy of PD-1 antibody in neoadjuvant chemoradiotherapy in microsatellite stable (MSS) locally advanced rectal cancer (LARC).
- Trial name
- NCT04411537
- Testing
- PD-1 antibody, Capecitabine, Irinotecan
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Metastatic Carcinoma in the Liver, MLH1 Gene Mutation
Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver
This pilot clinical trial studies the side effects and how well durvalumab and tremelimumab work in treating patients with microsatellite stable colorectal cancer that has spread to the liver.
- Conditions
- Metastatic Carcinoma in the Liver, MLH1 Gene Mutation, MSH6 Gene Mutation, PMS2 Gene Mutation
- Trial name
- NCT03005002
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Tremelimumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- City of Hope Medical Center
Colorectal Cancer
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
The primary objective of this study is to evaluate the effectiveness of zanzalintinib + Pembrolizumab (+) berahyaluronidase alfa and zanzalintinib alone compared with placebo.
- Trial name
- STELLAR-316 (NCT07750158)
- Testing
- Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa
- Where
- 13 sites in United States
- Volunteers
- 600 people
- Sponsor
- Exelixis